Antineoplastic drugs administered during pregnancy.
Cancer is the second leading cause of death in women during their reproductive years. Thus, antineoplastic drugs may be administered to pregnant women. The effects these agents have on the developing fetus depend on the type of agent and the timing of exposure during embryogenesis. In particular, antifolate antimetabolites should be avoided. However, the literature contains many reports of successful fetal outcomes after exposure to other types of agents. The decision to begin antineoplastic therapy must be carefully considered by all physicians and the patient involved.